First-in-Human Phase I Study of Aprutumab Ixadotin, a Fibroblast Growth Factor Receptor 2 Antibody–Drug Conjugate (BAY 1187982) in Patients with Advanced Cancer

Erdafitinib: First Global Approval

(2019) Anthony Markham   DRUGS

Clinical toxicity of antibody drug conjugates: a meta-analysis of payloads

(2017) Joanna C. Masters et al.   INVESTIGATIONAL NEW DRUGS

Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study

(2017) Lucia Nogova et al.   JOURNAL OF CLINICAL ONCOLOGY

Next generation antibody drugs: pursuit of the 'high-hanging fruit'

(2017) Paul J. Carter et al.   NATURE REVIEWS DRUG DISCOVERY

Strategies and challenges for the next generation of antibody–drug conjugates

(2017) Alain Beck et al.   NATURE REVIEWS DRUG DISCOVERY

Preclinical Efficacy of the Auristatin-Based Antibody–Drug Conjugate BAY 1187982 for the Treatment of FGFR2-Positive Solid Tumors

(2016) Anette Sommer et al.   CANCER RESEARCH

Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial

(2016) Sergio Amadori et al.   JOURNAL OF CLINICAL ONCOLOGY

Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates

(2016) Heather Donaghy   mAbs

Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia

(2016) Hagop M. Kantarjian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Peripheral neuropathy with microtubule inhibitor containing antibody drug conjugates: Challenges and perspectives in translatability from nonclinical toxicology studies to the clinic

(2016) Nicola J. Stagg et al.   REGULATORY TOXICOLOGY AND PHARMACOLOGY

Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application

(2016) Young Kwang Chae et al.   Oncotarget

Fibroblast growth factor receptor 2 expression, but not its genetic amplification, is associated with tumor growth and worse survival in esophagogastric junction adenocarcinoma

(2016) Ryuma Tokunaga et al.   Oncotarget

Rationale for targeting fibroblast growth factor receptor signaling in breast cancer

(2015) Fabrice André et al.   BREAST CANCER RESEARCH AND TREATMENT

Abstract 1683: Pharmacokinetic/pharmacodynamic (PK/PD) and toxicokinetic/toxicodynamic (TK/TD) modeling of preclinical data of FGFR2-ADC (BAY 1187982) to guide dosing in phase 1

(2015) Sabine Wittemer-Rump et al.   CANCER RESEARCH

Targeting FGFR Signaling in Cancer

(2015) M. Touat et al.   CLINICAL CANCER RESEARCH

Ocular Adverse Events Associated with Antibody–Drug Conjugates in Human Clinical Trials

(2015) Joshua Seth Eaton et al.   JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS

Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial

(2015) Craig H Moskowitz et al.   LANCET

Careless talk costs lives: fibroblast growth factor receptor signalling and the consequences of pathway malfunction

(2015) Edward P. Carter et al.   TRENDS IN CELL BIOLOGY

Personalized Ovarian Cancer Disease Surveillance and Detection of Candidate Therapeutic Drug Target in Circulating Tumor DNA

(2015) John A. Martignetti et al.   NEOPLASIA

Inhibition of fibroblast growth factor receptor 2 attenuates proliferation and invasion of pancreatic cancer

(2014) Yoko Matsuda et al.   CANCER SCIENCE

Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma

(2014) Nizar M. Tannir et al.   INVESTIGATIONAL NEW DRUGS

Downregulation of fibroblast growth factor receptor 2 and its isoforms correlates with a high proliferation rate and poor prognosis in high-grade glioma

(2014) RYUJI OHASHI et al.   ONCOLOGY REPORTS

The Next Generation of Antibody Drug Conjugates

(2014) Fiona Mack et al.   SEMINARS IN ONCOLOGY

Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors

(2013) R. Dienstmann et al.   ANNALS OF ONCOLOGY

Emergence of FGFR family gene fusions as therapeutic targets in a wide spectrum of solid tumours

(2013) Brittany C Parker et al.   JOURNAL OF PATHOLOGY

FGFR2 Promotes Breast Tumorigenicity through Maintenance of Breast Tumor-Initiating Cells

(2013) Sungeun Kim et al.   PLoS One

Serum D-Dimer Concentrations in Nephrotic Syndrome Track with Albuminuria, Not Estimated Glomerular Filtration Rate

(2012) D.J. Sexton et al.   AMERICAN JOURNAL OF NEPHROLOGY

Antibody-Drug Conjugates in Cancer Therapy

(2012) Eric L. Sievers et al.   Annual Review of Medicine

A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets

(2012) Niantao Deng et al.   GUT

Phase I Multidose-Escalation Study of the Anti-CD19 Maytansinoid Immunoconjugate SAR3419 Administered by Intravenous Infusion Every 3 Weeks to Patients With Relapsed/Refractory B-Cell Lymphoma

(2012) Anas Younes et al.   JOURNAL OF CLINICAL ONCOLOGY

Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma

(2012) Anas Younes et al.   JOURNAL OF CLINICAL ONCOLOGY

Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study

(2012) Sylvie Castaigne et al.   LANCET

Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

(2012) Sunil Verma et al.   NEW ENGLAND JOURNAL OF MEDICINE

Fibroblast growth factors and their receptors in cancer

(2011) Jørgen Wesche et al.   BIOCHEMICAL JOURNAL

Overexpressed fibroblast growth factor receptor 2 in the invasive front of colorectal cancer: A potential therapeutic target in colorectal cancer

(2011) Yoko Matsuda et al.   CANCER LETTERS

Trastuzumab Emtansine: A Unique Antibody-Drug Conjugate in Development for Human Epidermal Growth Factor Receptor 2-Positive Cancer

(2011) P. M. LoRusso et al.   CLINICAL CANCER RESEARCH

Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets

(2010) N Turner et al.   ONCOGENE

FGF10/FGFR2 signal induces cell migration and invasion in pancreatic cancer

(2008) S Nomura et al.   BRITISH JOURNAL OF CANCER

First line chemotherapy with planned sequential administration of gemcitabine followed by docetaxel in elderly advanced non-small-cell lung cancer patients: a multicenter phase II study

(2008) C Tibaldi et al.   BRITISH JOURNAL OF CANCER

High Absolute Risks and Predictors of Venous and Arterial Thromboembolic Events in Patients With Nephrotic Syndrome

(2007) Bakhtawar K. Mahmoodi et al.   CIRCULATION